The anti-PD-L1 × IL-2v fusion protein, conceived upon an innovative bispecific antibody platform, addresses the limitations of conventional IL-2 therapies by mitigating adverse effects while enhancing anti-tumor efficacy. Here, IL2 is linked to neoplasm.